Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4274437 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4268324 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4282241 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL2722434 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL111395 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL27946556 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4271266 | 1.00 | LMNA (0.35) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4274454 | 0.95 | TSHR (0.34) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4280281 | 0.95 | TSHR (0.34) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 | |
| SCHEMBL4272338 | 0.95 | TSHR (0.34) | LMNAL3MBTL1ALDH1A1PDE4ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654188-B2 | Glycotargeting therapeutics | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-05-23 | — | — | US | claimed |
| US-20090294362-A1 | STATIONARY PHASE FOR HYDROPHILIC INTERACTION CHROMATOGRAPHY | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | claimed |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-04-30 | — | — | US | disclosed |
| US-20260034226-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20260007723-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-01-08 | — | — | US | disclosed |
| US-20250295743-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2025-09-25 | — | — | US | disclosed |
| CN-119350116-A | Method for synthesizing itaconic acid compound | 南京工业大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-115850076-B | Method for introducing difluoromethylene into aromatic ring of allyl ester compound | 南京工业大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118576700-A | Sugar-targeted therapeutic agents | 洛桑聚合联合学院 | 2024-09-03 | — | — | CN | disclosed |
| CN-118436774-A | Sugar-targeted therapeutic agents | 洛桑聚合联合学院 | 2024-08-06 | — | — | CN | disclosed |
| EP-4385520-A2 | GLYCOTARGETING THERAPEUTICS | Ecole Polytechnique Fédérale de Lausanne (CH) | 2024-06-19 | — | — | EP | disclosed |
| US-20160243248-A1 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECHNIQUE FED DE LAUSANNE (EPFL) (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20160015821-A1 | GLYCOTARGETING THERAPEUTICS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-01-21 | — | — | US | disclosed |
| WO-2015140648-A2 | GLYCOTARGETING THERAPEUTICS | ECOLE POLYTECNIQUE FEDERALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2015-09-24 | — | — | WO | disclosed |
| US-8637468-B2 | Synthetic cholesterylamine-linker derivatives for agent delivery into cells | THE UNIVERSITY OF KANSAS (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013109907-A1 | DRUG AND IMAGING AGENT DELIVERY COMPOSITIONS AND METHODS | UNIVERSITY OF KANSAS (US) | 2013-07-25 | — | — | WO | disclosed |
| US-20120208771-A1 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2011019942-A2 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS | UNIVERSITY OF KANSAS (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20090294362-A1 | STATIONARY PHASE FOR HYDROPHILIC INTERACTION CHROMATOGRAPHY | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| EP-0237132-A2 | Process for the preparation of water-soluble saccharide polymers | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295743-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885L3MBTL1 2270/4885ALDH1A1 2577/4885 |
| US-20160243248-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885L3MBTL1 2270/4885ALDH1A1 2577/4885 |
| US-20120208771-A1 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS | NPC1L1, CETP, CYP46A1 | LMNA 339/4885L3MBTL1 1753/4885ALDH1A1 4461/4885 |
| US-20260034226-A1 | GLYCOTARGETING THERAPEUTICS | LGALS1, ST6GAL1, LGALS2 | LMNA 4291/4885L3MBTL1 1057/4885ALDH1A1 460/4885 |
| US-20260007723-A1 | GLYCOTARGETING THERAPEUTICS | HLA-DRB1, CD74, MICA | LMNA 4463/4885L3MBTL1 571/4885ALDH1A1 1398/4885 |
| US-11654188-B2 | Glycotargeting therapeutics | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885L3MBTL1 2270/4885ALDH1A1 2577/4885 |
| US-20260115300-A1 | GLYCOTARGETING THERAPEUTICS | CD74, HLA-DRB1, CD69 | LMNA 4625/4885L3MBTL1 2352/4885ALDH1A1 555/4885 |
| US-20160015821-A1 | GLYCOTARGETING THERAPEUTICS | B3GAT3, UGGT1, MRGPRX1 | LMNA 4804/4885L3MBTL1 2270/4885ALDH1A1 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.